CoChat
Sign Up
Cited by 44Advanced MRI Techniques and ApplicationsCharacterization and Applications of Magnetic NanoparticlesMRI in cancer diagnosis

MR imaging of the liver and spleen: a comparison of the effects on signal intensity of two superparamagnetic iron oxide agents

Chen, F, Ward, J, Robinson, P.J·1999·Magnetic Resonance Imaging
DOI 10.1016/s0730-725x(98)00193-3
Open this paper in CoChat — free account

Abstract

We compared the effects of two superparamagnetic iron oxide (SPIO) contrast agents, ferumoxides and SHU-555A, in MR imaging of the liver and spleen. Thirty-six patients with known malignant lesions of the liver underwent T2W turbo spin-echo (TSE) and T1WGRE FLASH opposed-phase imaging before and after SPIO injection on a 1.0 T MR system. Post-ferumoxides images were obtained in 18 patients 90 min after infusion of 15 micrommol Fe/kg of the agent. In 18 other patients SHU-555A was administered as a rapid bolus at a dose of 7.0-12.9 micrommol Fe/kg. T1WGRE FLASH images were obtained immediately, 30 s and 480 s and T2WTSE images 10 min after injection. Signal intensity of the liver, spleen, and malignant liver lesions before and after SPIO was measured with operator-defined regions of interest. The effects of ferumoxides and SHU-555A were measured as the percentage signal intensity change (PSIC) and in the malignant liver lesions additionally as changes in lesion-to-liver contrast-to-noise ratio (deltaDCNR). On T2W TSE images, there was no significant difference between the two agents in signal loss of liver parenchyma (p > 0.05). The signal loss in the spleen produced by ferumoxides was greater than with SHU-555A (p < 0.05). Both SPIO agents produced a significant increase in the CNR of malignant liver lesions. Delta CNR was slightly greater with ferumoxides than with SHU-555A (p < 0.05). On T1WGRE FLASH images, a slight decrease of liver SI induced by both agents was found on late post-SPIO images. No significant difference of liver PSIC between the two SPIO agents was noted on T1W images. The SI of spleen was significantly increased with both agents on T1W images and no difference in PSIC of spleen was noted (p > 0.05). The T1 and T2 effects produced by ferumoxides and SHU-555A were comparable in the liver although ferumoxides produced a stronger T2 effect in the spleen.

Integrity signals

Registry

Crossref · 10.1016/s0730-725x(98)00193-3

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Chen et al. found no significant difference in signal intensity in livers on T2-weighted images for ferucarbotran and ferumoxide.

    “When compared with each other, Chen et al. found no significant difference in signal intensity in livers on T2-weighted images for both compounds.”

    From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [148]

  • SPION have been extensively used for diagnostic purposes, for visualizing tumors and metastases in liver, spleen and lymph nodes, for angiography as a blood pool agent, and for visualizing inflammatory lesions like atherosclerotic plaques.

    “SPION have been extensively used for diagnostic purposes, for visualizing tumors and metastases in liver, spleen and lymph nodes [137, 138], for angiography as a blood pool agent [139] and for visualizing inflammatory lesions like atherosclerotic plaques [140].”

    From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [137]

  • The determined signal intensity for ferucarbotran in the spleen was lower than for ferumoxide, due to overall lower uptake in this organ resulting from the smaller size and lower dose administered for ferucarbotran.

    “In contrast, the determined signal intensity for ferucarbotran in the spleen was lower than for ferumoxide, due to an overall lower uptake in this organ, resulting from the smaller size and lower dose administered for ferucarbotran.”

    From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [148]

  • In patients with liver metastasis originating from colorectal cancer, the change in contrast-to-noise was compared for both SPION, showing a slightly less favorable contrast-to-noise ratio for ferucarbotran.

    “In patients with liver metastasis originating from colorectal cancer, the change in contrast-to-noise was also compared for both SPION, showing a slightly less favorable contrast-to-noise ratio for ferucarbotran [148].”

    From Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications (2019) · cites this paper as [148]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Chen, F., Ward, J., & Robinson, P. J.
Affiliations
St James's University Hospital (GB)
Corresponding author
Robinson, P.J
ORCID
Chen, F
Venue
Magnetic Resonance Imaging
Publisher
Elsevier BV
Published
1999-05
Volume
17
Issue
4
Pages
549-556
ISSN
0730-725X (ISSN-L)
DOI
10.1016/s0730-725x(98)00193-3
OpenAlex
W2108830163
Cited by
44
References
24
Citations by year
2025: 2 · 2024: 2 · 2023: 1 · 2021: 4 · 2020: 3 · 2019: 2 · 2016: 1 · 2015: 1
FWCI
0.96
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Magnetic Resonance Imaging (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
  • Physical Sciences › Engineering › Biomedical Engineering › Characterization and Applications of Magnetic Nanoparticles
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
Keywords
superparamagnetic iron oxide contrast agent, ferumoxides, liver MRI, liver cancer, signal intensity, contrast-to-noise ratio, T2-weighted imaging, T1-weighted imaging
MeSH terms
Contrast Media, Dextrans, Female, Humans, Iron, Liver, Liver Neoplasms, Magnetic Resonance Imaging, Male, Middle Aged, Oxides, Spleen, Suspensions, Ferrosoferric Oxide, Magnetite Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review